Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Donna Bannavong"'
Autor:
Mai H. Le, Sharron Gargosky, Erica Browning, Donna Bannavong, Kaitlin Zablotsky, Melinda L. Telli, David A. Canton, Irene Wapnir
Publikováno v:
Cancer Research. 79:P2-09
Introduction: Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer diagnoses and is associated with a higher risk of recurrence and more aggressive course in the metastatic setting. Emerging data suggest that some pati
Autor:
Christopher Stuart Baker, Jack Lee, Tom Van Hagen, Victoria Atkinson, Bernard A. Fox, Carmen Ballesteros-Merino, Eric D. Whitman, Kellie Malloy Foerter, Reneta Hermiz, Sajeve Thomas, Scott J. Diede, Elizabeth Buchbinder, Katy K. Tsai, Catalin Mihalcioiu, Shawn M. Jensen, Rachel Roberts-Thomson, Sandra Aung, David A. Canton, Alain Algazi, Christopher G. Twitty, Mecker G. Möller, Clemens Krepler, Donna Bannavong, Emmett V. Schmidt, Marcus O. Butler, John R. Hyngstrom, Erica Browning, Jon Salazar, M. Shaheen, Adil Daud, Matteo S. Carlino, Andrew Mant, C. Lance Cowey, Gregory A. Daniels, Lauren Svenson, Pablo Fernandez-Penas, Igor Puzanov, Jendy Sell, Andrew Haydon
Publikováno v:
Late-breaking abstracts.
Background Electroporated plasmid IL-12 (TAVO or tavokinogene telseplasmid) is a novel pro-inflammatory intratumoral therapy with substantial single agent activity in melanoma, which has been shown to synergize with anti-PD-1 antibodies in patients p
Autor:
Mark B. Faries, Sanjiv S. Agarwala, Bernard A. Fox, Carlo Bifulco, Sharron Gargosky, Donna Bannavong, Christopher G. Twitty, Erica Browning, M. Molina, R. Talia, M.H. Le, Arielle Oglesby, Lawrence Fong, Adil Daud, Katy K. Tsai, Alain Algazi, Carmen Ballesteros-Merino, Shailender Bhatia, M. Franco, Karl D. Lewis, Lauren P. Levine, Robert H. Pierce
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology, vol 31, iss 4
Background Interleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity. We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT 01502293). Patients and method